Skip to content
Business

EQT Agrees to Take Qiagen Private in a €10.8bn Deal at €46.50 a Share

EQT, backed by ADIA and CPP Investments, has agreed an all-cash offer for diagnostics group Qiagen at €46.50 a share, valuing it at about €10.8bn including debt, with both boards in support.

QIAGEN's curved white headquarters building with autumn trees in front, under a clear blue sky.
Photo: QIAGEN

Swedish private equity group EQT has agreed to buy Qiagen, the German-Dutch maker of molecular testing and sample-preparation products, in an all-cash deal worth about €10.8bn including debt. The offer of €46.50 a share was announced on Wednesday evening with the unanimous support of Qiagen's two boards. If it succeeds, one of Europe's best-known life sciences companies will leave both the Frankfurt and New York stock exchanges.

The offer

  • €46.50 a share in cash
  • €10.8bn enterprise value, about $12.1bn
  • 40.3% premium to the undisturbed share price

The Terms of the Offer

The bidder is Crown NL Bidco, a holding company indirectly controlled by the EQT XI fund. Two large state-backed investors are joining as co-investors: Luxinva, a wholly owned subsidiary of the Abu Dhabi Investment Authority, and CPP Investment Board Europe, part of Canada's CPP Investments.

The enterprise value of about €10.8bn includes roughly $1.1bn of net debt. The price is measured against the Xetra close of €33.15 on 8 July 2026, the last trading day before reports of private equity interest in the company. On that basis the premium is 40.3%. Against the three-month volume-weighted average price up to that date, €31.66, it is 46.9%.

Qiagen said its Supervisory Board and Managing Board reached their decision after a strategic review that included talks with both strategic and financial parties. Both boards will recommend that shareholders accept.

EQT says it has committed equity and debt financing in place, and the offer carries no financing condition. Morgan Stanley, Jefferies, Deutsche Bank, SMBC, Crédit Agricole and UniCredit are backing the debt.

A gloved QIAGEN worker in a blue gown lifts a labelled reagent cartridge from a yellow tray in a production area, with a second gowned worker behind.
A gloved QIAGEN worker in a blue gown lifts a labelled reagent cartridge from a yellow tray in a production area, with a second gowned worker behind. Photo: QIAGEN

What Has to Happen Before Closing

The offer needs acceptances covering at least 50% of Qiagen's share capital plus one share. It also depends on shareholders approving a set of post-closing measures at an extraordinary general meeting, and on merger control and foreign investment clearances.

Germany's financial regulator BaFin must approve the offer document before the acceptance period begins. Because of the New York listing, a parallel US offer will be launched, with a tender offer statement filed with the Securities and Exchange Commission.

The post-closing measures are how the buyer would reach full ownership. If the meeting backs them with at least 80% of votes cast, the boards will go ahead. If support is lower, they may still proceed if they judge it to be in Qiagen's interest and there is substantial majority support. Shareholders who did not tender would then receive a cash distribution equal to the offer price, less any withholding tax. The listings in Frankfurt and New York would end.

Key conditions and dates

  • Minimum acceptance: 50% of share capital plus one share
  • Shareholder vote on post-closing measures during the acceptance period
  • Merger control and foreign investment approvals required
  • Closing expected in mid-2027
  • Possible interim dividend of up to $0.47 a share if approvals take more than 10 months

Closing is expected in mid-2027. Because that is some way off, the agreement allows Qiagen to pay an interim dividend of up to $0.47 a share if closing has not happened within 10 months of the announcement because regulatory approvals are still pending. That payment would not be deducted from the offer price.

Why EQT Wants Qiagen

Qiagen sells the tools used to extract and analyse DNA and RNA in research labs, hospitals and testing centres. It serves more than 500,000 customers and employed about 5,400 people at more than 35 locations at the end of September.

EQT, which manages about €354bn, has invested more than €30bn in over 210 healthcare companies. Its past and current holdings include Galderma, Parexel, Aldevron, Dako and HemoCue. Matteo Thun-Hohenstein, a partner at EQT, called Qiagen a global leader in life science tools and diagnostics.

EQT has made commitments on Qiagen's strategy, key brands, operating footprint, research and development, employees and corporate culture. The company is expected to keep its name, and its current management will continue to run it independently until the deal closes.

Chief executive Jonathan M. Pratt argued that private ownership would let the company "move faster and have greater freedom" to invest behind its priorities. The usual case for a take-private is that long-term spending on new instruments and tests can be planned without the pressure of quarterly reporting.

What It Means for Shareholders

For investors the offer sets a reference point well above where the shares traded before the summer reports. The 40% premium is measured against the undisturbed July price, so it says nothing about how far the shares may have moved since takeover talk began.

Several steps still lie ahead. The offer document, with the exact acceptance period, is yet to be published. Shareholders will then decide whether to tender or wait, knowing that the post-closing measures are designed to bring in those who do not. Because the cash distribution to those who stay out is paid after any withholding tax, the details in the offer document will matter. The announcement also lists the possibility of a competing offer among the risks to the deal.

Sources

Related stories

Business

Red Cat Holdings Wins Steyr Motors Board Backing for Its €205m Takeover Offer

Steyr Motors' boards urged shareholders to accept Red Cat Holdings' €39-a-share cash offer, worth about €205m, for the Austrian engine maker. Acceptances close on 18 December.

Business

Athabasca Oil Agrees to a C$5.7bn Takeover by Cenovus at C$12 a Share

Cenovus Energy will pay C$12 a share in cash and stock for the Alberta thermal oil producer, a 14% premium to its 20-day average price. Athabasca shares rose almost 14% on the…

Business

Québecor Makes a C$31bn Cash-and-Share Bid for Telus, Which Warns of Regulatory Risk

Québecor has offered C$6.35 in cash plus 0.17 of its own shares for each Telus share, a bid worth about C$31bn. The Telus board says the price falls short and the regulatory risk…

Business

SAP Revenue Passes €10bn in the Third Quarter as Cloud Sales Grow 26%

SAP's third-quarter revenue rose 13 percent to €10.27 billion as cloud sales grew 26 percent, and the group now expects 2026 cloud revenue at the top end of its €25.8 to €26.2…

Business

Québecor Makes a C$31bn Cash-and-Share Bid for Telus, Which Warns of Regulatory Risk

Québecor has offered C$6.35 in cash plus 0.17 of its own shares for each Telus share, a bid worth about C$31bn. The Telus board says the price falls short and the regulatory risk…

Business

Tyson Foods Shares Jump 8.7% as Beef Outlook Outweighs a $74m Quarterly Loss

Tyson Foods posted a $74m fourth-quarter net loss and adjusted EPS of $0.61, down 47%, yet its shares closed 8.7% higher on Monday as its 2027 beef outlook pointed to far smaller…

Business

Roche Wins FDA Approval for Breast Cancer Pill Wilserdly After 62% Cut in Progression Risk

The FDA approved Roche's all-pill Wilserdly combination for ESR1-mutated advanced breast cancer after it cut the risk of progression or death by 62%. A ruling on early-stage use is…

Business

ULA Loses Its First Mission as Vulcan Rocket Fails With 40 Amazon Leo Satellites on Board

United Launch Alliance's Vulcan rocket failed about 10 minutes after lift-off on Sunday, and all 40 Amazon Leo satellites were lost. Amazon fell 3.3% on Monday as space stocks…